Wealthfront Advisers LLC Catalyst Pharmaceuticals, Inc. Transaction History
Wealthfront Advisers LLC
- $120 Billion
- Q4 2024
A detailed history of Wealthfront Advisers LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealthfront Advisers LLC holds 135,422 shares of CPRX stock, worth $3.05 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
135,422Holding current value
$3.05 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
344Shares Held
98.4MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$421 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$190 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$131 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$70.6 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$67.9 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.32B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...